08:32 AM EST, 11/25/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday a phase 2 trial of its experimental drug amycretin in people with type 2 diabetes showed reductions in weight and HbA1c or average blood sugar.

From starting HbA1c levels of about 7.8% with weekly injections and 8.0% with daily pills, amycretin lowered HbA1c by up to 1.8% and 1.5% respectively by week 36, helped up to 89% and 78% of patients get below 7%, compared with 0.2% to 0.4% reductions on placebo, the company said.

Injectable amycretin led to weight loss of up to 14.5% from roughly 99 kilograms at baseline versus 2.6% on placebo, while oral doses produced losses of up to 10.1% from about 101 kilograms compared with 2.5% on placebo, and higher doses had not yet plateaued by week 36, Novo said.

Both injectable and oral forms had a safety profile similar to other incretin and amylin-based drugs, with mostly mild to moderate gastrointestinal events, the company added.

Based on the findings, Novo Nordisk ( NVO ) plans to start a phase 3 development program with amycretin for adults with type 2 diabetes in 2026, it said.

Shares of the company were up over 2% in recent Tuesday premarket activity.